See also this year's filing and all EDGAR filings for this company.
PDF Report 0000320017_2019_Lisata_Therapeutics_INC.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 8.678415126370268e-07, 'aggregate_val': 63375682, 'exp_sum': 63375627, 'exp_to_value': {'IntangibleAssets': 0, 'AssetsNonCurrent': 1434077, 'AssetsCurrent': 61109645, 'PropertyPlantAndEquipment': 256905, 'remainder_Assets': 575000}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000320017, Lisata Therapeutics INC
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 309,000 |
| 2 | AssetsCurrent | 44,106,000 |
| 3 | PropertyPlantAndEquipment | 165,000 |
| 4 | remainder_Assets | 0 |
| 5 | LongTermLiabilities | 1,507,000 |
| 6 | LiabilitiesCurrent | 5,619,000 |
| 7 | remainder_Liabilities | 0 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 0 |
| 10 | GeneralAndAdministrativeExpense | 9,393,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 7,594,000 |
| 16 | remainder_Expenses | 0 |
| 17 | remainder_Revenues | 0 |
| 18 | remainder_NetIncome | 819,000 |
| 19 | remainder_ComprehensiveNetIncome | -3,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 44,580,000 |
| 1 | Liabilities | 7,126,000 |
| 2 | Expenses | 16,987,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 37,454,000 |
| 5 | NetIncome | -16,168,000 |
| 6 | ComprehensiveNetIncome | -16,171,000 |
| 7 | BaseVar | 34,757,500 |
| 8 | EconomicCapitalRatio | 3.40 |
Edgar->Model Mapping
Feature Distribution
Change over Time
